Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.
Frequently asked questions
What sector does Prostatype Genomics AB (PROGEN) operate in?
Prostatype Genomics AB belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Prostatype Genomics AB (PROGEN) current stock price?
As of the latest data, Prostatype Genomics AB stock price is SEK 0.10, with a previous close of SEK 0.10. Prostatype Genomics AB lost -SEK 0.00 in the last trading session, representing a -1.42% loss.
What is Prostatype Genomics AB (PROGEN) current market capitalization?
Prostatype Genomics AB market cap is approximately 15.09 million.
What is Prostatype Genomics AB (PROGEN) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.52.
Does Prostatype Genomics AB (PROGEN) pay dividends?
No. Prostatype Genomics AB does not pay a dividend.
What is Prostatype Genomics AB (PROGEN) beta (volatility) score?
Prostatype Genomics AB has a beta of 1.409, suggesting it is more volatile than the market.
